{
    "4176181": {
        "id": 4176181,
        "significance": "1",
        "headline": "Mylan NV Mylan Exec Expects Some Impact From Coronavirus Due To Global Nature Of Business Says Business Exposure In China Is Limited- Conf. Call",
        "description": "Feb 27 (Reuters) - Mylan NV <MYL.O>::MYLAN EXEC EXPECTS SOME IMPACT FROM CORONAVIRUS DUE TO GLOBAL NATURE OF BUSINESS; SAYS BUSINESS EXPOSURE IN CHINA IS LIMITED- CONF. CALL.MYLAN EXEC SAYS DOES NOT SEE ANY IMPACT OF FDA INSPECTION OF BIOCON MANUFACTURING PLANT ON COMMERCIALIZATION PLANS FOR INSULIN GLARGINE IN THE U.S.- CONF. CALL.EXEC SAYS TOO EARLY TO PREDICT ANY COMMERCIAL IMPACT DUE TO THE CORONAVIRUS TO OPERATIONS AROUND THE GLOBE - CONF. CALL.EXEC SAYS BIOSIMILARS WILL CONTINUE TO BE A GROWTH DRIVER AFTER PFIZER UNIT MERGER- CONF. CALL.EXEC DOES NOT SEE ANY CORONAVIRUS IMPACT IN NEAR FUTURE; SAYS IF SITUATION CONTINUES OVER NEXT COUPLE OF MONTHS, SEES IMPACT RELATED TO DRUG SHORTAGES- CONF. CALL.MYLAN EXEC SEEING LOGISTICAL ISSUES DUE TO CORONAVIRUS, BUT NOT SEEING ISSUES WITH PRODUCTION OR PRICE INCREASES OF ACTIVE INGREDIENTS - CONF CALL.",
        "parentTopics": "Corporate Guidance"
    },
    "4176016": {
        "id": 4176016,
        "significance": "1",
        "headline": "Mylan Reports Qtrly Earnings Per Share $0.04",
        "description": "Feb 27 (Reuters) - Mylan NV <MYL.O>::MYLAN REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS AND PROVIDES 2020 GUIDANCE.QTRLY TOTAL REVENUES OF $3.19 BILLION, UP 4%, UP 5% ON A CONSTANT CURRENCY BASIS, COMPARED TO PRIOR YEAR PERIOD.SEES 2020 TOTAL REVENUES BETWEEN $11.5 BILLION AND $12.5 BILLION..QTRLY EARNINGS PER SHARE $0.04.Q4 ADJUSTED EARNINGS PER SHARE $1.40.SEES 2020 ADJUSTED EBITDA BETWEEN $3.2 BILLION AND $3.9 BILLION..QTRLY ADJUSTED EARNINGS PER SHARE $1.40.Q4 EARNINGS PER SHARE VIEW $1.28, REVENUE VIEW $3.23 BILLION -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $11.92 BILLION -- REFINITIV IBES DATA.MID-POINT OF GUIDANCE IS IN LINE WITH WHAT WE PREVIOUSLY DISCLOSED FOR 2020 IN CONJUNCTION WITH UPJOHN TRANSACTION.",
        "parentTopics": "Corporate Guidance"
    },
    "4216118": {
        "id": 4216118,
        "significance": "1",
        "headline": "Mylan Reports First Quarter 2020 Results And Reaffirms 2020 Guidance",
        "description": "Mylan Nv <MYL.O>::MYLAN REPORTS FIRST QUARTER 2020 RESULTS AND REAFFIRMS 2020 GUIDANCE.Q1 REVENUE ROSE 5 PERCENT TO $2.62 BILLION.Q1 TOTAL REVENUES OF $2.62 BILLION, UP 5%, UP 8% ON A CONSTANT CURRENCY BASIS, COMPARED TO PRIOR YEAR PERIOD..Q1 NORTH AMERICA SEGMENT NET SALES OF $955.5 MILLION, UP 4% ON AN ACTUAL AND CONSTANT CURRENCY BASIS.QTRLY EARNINGS PER SHARE $0.04.CURRENTLY DEVELOPING DETAILS RESTRUCTURING PROGRAM, INCLUDING WORKFORCE ACTIONS AND OTHER RESTRUCTURING ACTIVITIES.DELAYED IMPLEMENTATION OF 2020 RESTRUCTURING PROGRAM..Q1 REVENUE VIEW $2.64 BILLION -- REFINITIV IBES DATA.REMAIN ON TRACK TO CLOSE PENDING COMBINATION WITH PFIZER'S UPJOHN BUSINESS IN SECOND HALF OF 2020.AT THIS TIME, CO DOES NOT FORESEE ANY SUPPLY DISRUPTIONS.CONTINUE TO TARGET APPROXIMATELY $1 BILLION OF DEBT REPAYMENT DURING 2020.ALL OF CO'S MANUFACTURING FACILITIES ARE CURRENTLY OPERATIONAL.AT THIS TIME, CO HAS SUFFICIENT SAFETY STOCK TO ADDRESS CURRENT NEEDS..CURRENTLY ARE NOT EXPERIENCING ANY SIGNIFICANT NEGATIVE IMPACT ON OVERALL GLOBAL DEMAND TRENDS.DO NOT SEE ANY NEGATIVE LIQUIDITY TRENDS RELATED TO COVID-19 PANDEMIC.INVENTORY LEVELS REMAIN IN-LINE WITH NORMAL LEVELS AND ARE CURRENTLY ASSESSED TO BE SUFFICIENT FOR ANTICIPATED DEMAND.DONATING 10 MILLION TABLETS OF HYDROXYCHLOROQUINE SULFATE TO HHS.DONATING HYDROXYCHLOROQUINE SULFATE TABLETS TO WORLD HEALTH ORGANIZATION.BELIEVE THAT CURRENTLY HAVE, AND WILL MAINTAIN, ABILITY TO MEET FORESEEABLE LIQUIDITY NEEDS.",
        "parentTopics": "Corporate Guidance"
    },
    "4229367": {
        "id": 4229367,
        "significance": "1",
        "headline": "Mylan NV Says CEO's 2019 Total Compensation Was $18.5 Mln Vs $13.3 Mln In 2018 \u2013 SEC Filing",
        "description": "June 8 (Reuters) - Mylan NV <MYL.O>::MYLAN NV SAYS CEO HEATHER BRESCH'S 2019 TOTAL COMPENSATION WAS $18.5 MILLION VERSUS $13.3 MILLION IN 2018 \u2013 SEC FILING.MYLAN NV SAYS CFO KENNETH S. PARKS' 2019 TOTAL COMPENSATION WAS $5.6 MILLION VERSUS $4.4 MILLION IN 2018.MYLAN NV SAYS PRESIDENT RAJIV MALIK'S 2019 TOTAL COMPENSATION WAS $12.4 MILLION VERSUS $9.5 MILLION IN 2018.MYLAN NV - FOR FY 2019, RATIO OF MEDIAN EMPLOYEE TOTAL ANNUAL COMPENSATION TO CEO TOTAL ANNUAL COMPENSATION OF 427 TO 1.",
        "parentTopics": "Restructuring\\/Reorganization\\/Related"
    },
    "4256788": {
        "id": 4256788,
        "significance": "1",
        "headline": "Mylan NV Posts Quarterly Earnings Per Share $0.08",
        "description": "Aug 6 (Reuters) - Mylan NV <MYL.O>::MYLAN REPORTS STRONG SECOND QUARTER AND FIRST HALF 2020 RESULTS AND UPDATES 2020 GUIDANCE.QTRLY TOTAL REVENUES OF $2.73 BILLION, DOWN 4%.QTRLY NORTH AMERICA SEGMENT NET SALES OF $1.04 BILLION, UP 2% ON AN ACTUAL AND CONSTANT CURRENCY BASIS..QTRLY EARNINGS PER SHARE $0.08.QTRLY EUROPE SEGMENT NET SALES OF $935.0 MILLION, DOWN 6%, DOWN 3% ON A CONSTANT CURRENCY BASIS.QTRLY REST OF WORLD SEGMENT NET SALES OF $721.9 MILLION, DOWN 10%.SEES FY REVENUE $11.5 BILLION TO $12 BILLION.NOW EXPECT OVERALL COVID-19 RECOVERY EFFORTS WILL OCCUR SLOWER THAN ANTICIPATED.TIGHTENING FY ADJUSTED EBITDA GUIDANCE RANGE TO BETWEEN $3.30 TO $3.70 BILLION.FY2020 REVENUE VIEW $11.62 BILLION -- REFINITIV IBES DATA.QTRLY ADJUSTED NET EARNINGS OF $574.3 MILLION, COMPARED TO ADJUSTED NET EARNINGS OF $532.8 MILLION IN THE PRIOR YEAR PERIOD..EXPECT OVERALL COVID-19 RECOVERY EFFORTS MAY CONTINUE THROUGHOUT REST OF YEAR.CONTINUE TO EXPECT FULL YEAR ADJUSTED FREE CASH FLOW GENERATION TO BE CONSISTENT WITH 2019 LEVELS.ONTINUES TO PROGRESS TOWARD A SUCCESSFUL DEAL CLOSE WITH PFIZER'S UPJOHN BUSINESS IN Q4 OF THIS YEAR.KEN PARKS WILL DEPART EFFECTIVE SEPTEMBER 1, 2020.MYLAN -  UPON PARK'S TRANSITION, PAUL CAMPBELL, CONTROLLER AND CHIEF ACCOUNTING OFFICER OF CO , WILL LEAD GLOBAL FINANCE FUNCTIONS ON INTERIM BASIS.PFIZER AND CO AGREED SUBSEQUENT TO JUNE 30 TO EXTEND EPIPEN SUPPLY AGREEMENT FOR ADDITIONAL FOUR-YEAR PERIOD THROUGH DECEMBER 31, 2024.",
        "parentTopics": "Restructuring\\/Reorganization\\/Related"
    },
    "4300349": {
        "id": 4300349,
        "significance": "1",
        "headline": "Mylan Reports Qtrly Earnings Per Share $0.36",
        "description": "Nov 6 (Reuters) - Mylan NV <MYL.O>::MYLAN ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND LOOKS AHEAD TO THE LAUNCH OF VIATRIS INC..QTRLY TOTAL REVENUES OF $2.97 BILLION, A SLIGHT INCREASE ON AN ACTUAL BASIS AND A SLIGHT DECREASE ON A CONSTANT CURRENCY BASIS.QTRLY EARNINGS PER SHARE $0.36.Q3 EARNINGS PER SHARE VIEW $1.16, REVENUE VIEW $3.00 BILLION -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4347063": {
        "id": 4347063,
        "significance": "1",
        "headline": "Viatris Inc. Announces 2021 Financial Guidance And Reaffirms Strategic And Financial Commitments",
        "description": "Feb 22 (Reuters) - Viatris Inc <VTRS.O>::VIATRIS INC. ANNOUNCES 2021 FINANCIAL GUIDANCE AND REAFFIRMS STRATEGIC AND FINANCIAL COMMITMENTS.VIATRIS INC SEES 2021 REVENUE $17.2 BILLION - $17.8 BILLION.VIATRIS INC SEES 2021 ADJUSTED EBIDTA $6.0 - $6.4 BILLION.VIATRIS INC - INITIATING 2021 DIVIDEND AND REAFFIRMING CAPITAL ALLOCATION PRIORITIES.VIATRIS INC - BOARD EXPECTS CO TO PAY ANNUALIZED DIVIDEND OF APPROXIMATELY $540 MILLION, OR $0.44\\/SHARE.VIATRIS INC - EXPECTS TO REPAY APPROXIMATELY $6.5 BILLION IN DEBT BY END OF 2023.VIATRIS INC - TARGETING A LONG-TERM LEVERAGE RATIO OF 2.5X, WITH A RANGE OF 2.2X TO 2.8X..",
        "parentTopics": "Financing"
    },
    "4387292": {
        "id": 4387292,
        "significance": "1",
        "headline": "Viatris Inc. Reports Q1 Sales Of $4.4 Bln",
        "description": "May 10 (Reuters) - Viatris Inc <VTRS.O>::REPORTS STRONG FIRST QUARTER 2021 FINANCIAL RESULTS, REAFFIRMS 2021 GUIDANCE AND ANNOUNCES INAUGURAL QUARTERLY DIVIDEND.Q1 SALES $4.4 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.18 BILLION.SETS QUARTERLY DIVIDEND OF $0.11PER SHARE.REAFFIRMS FINANCIAL GUIDANCE FOR 2021.REMAINS ON TRACK TO ACHIEVE APPROXIMATELY $500 MILLION IN SYNERGIES IN 2021.QTRLY LOSS PER SHARE $0.86.",
        "parentTopics": "Corporate Guidance"
    },
    "4427566": {
        "id": 4427566,
        "significance": "1",
        "headline": "Viatris Reports Strong Second Quarter Results",
        "description": "Aug 9 (Reuters) - Viatris Inc <VTRS.O>::VIATRIS REPORTS STRONG SECOND QUARTER RESULTS.Q2 REVENUE $4.58 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.38 BILLION.RAISES 2021 FINANCIAL GUIDANCE.RAISES 2021 TOTAL REVENUES GUIDANCE RANGE TO $17.5 BILLION TO $17.9 BILLION.RAISES FY ADJUSTED EBITDA GUIDANCE RANGE TO $6.15 BILLION TO $6.45 BILLION.RAISES 2021 FREE CASH FLOW GUIDANCE RANGE TO $2.2 BILLION TO $2.4 BILLION.DECLARES QUARTERLY DIVIDEND OF ELEVEN CENTS.QTRLY LOSS PER SHARE $0.23.Q2 EARNINGS PER SHARE VIEW $0.87 -- REFINITIV IBES DATA.FY2021 REVENUE VIEW $17.60 BILLION -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4467407": {
        "id": 4467407,
        "significance": "1",
        "headline": "Viatris Reports Strong Third Quarter Results",
        "description": "Nov 8 (Reuters) - Viatris Inc <VTRS.O>::VIATRIS REPORTS STRONG THIRD QUARTER RESULTS, RAISES 2021 FINANCIAL GUIDANCE AND ANNOUNCES VIRTUAL INVESTOR EVENT ON JANUARY 7, 2022.Q3 REVENUE $4.54 BILLION.SEES 2021 TOTAL REVENUES GUIDANCE RANGE TO $17.70 BILLION TO $17.90 BILLION.Q3 REVENUE VIEW $4.39 BILLION -- REFINITIV IBES DATA.FY2021 REVENUE VIEW $17.82 BILLION -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4512784": {
        "id": 4512784,
        "significance": "1",
        "headline": "Viatris Reports Strong Fourth Quarter And Full-Year 2021 Financial Results Issues 2022 Financial Guidance Completes Comprehensive Strategic Review Unveils Plan To Reshape The Company For The Fut",
        "description": "Feb 28 (Reuters) - Viatris Inc <VTRS.O>::VIATRIS REPORTS STRONG FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS; ISSUES 2022 FINANCIAL GUIDANCE; COMPLETES COMPREHENSIVE STRATEGIC REVIEW; UNVEILS PLAN TO RESHAPE THE COMPANY FOR THE FUTURE; ANNOUNCES COMBINATION OF ITS BIOSIMILARS PORTFOLIO WI.PURSUANT TO TRANSACTION DOCUMENTS, BIOCON BIOLOGICS WILL TARGET AN INITIAL PUBLIC OFFERING (IPO) IN INDIA AS EARLY AS LATE 2023.SEES 2022 TOTAL REVENUE $17.0 BILLION - $17.5 BILLION.RECORDED AN ACCRUAL OF APPROXIMATELY $264.0 MILLION RELATED TO EPIPEN LITIGATION IN 2021.SEES 2022 ADJUSTED EBITDA $5.8 BILLION - $6.2 BILLION.QTRLY TOTAL NET SALES $4,331.3 MILLION VERSUS $3,587.7 MILLION.QTRLY LOSS PER SHARE $0.22.QTRLY TOTAL NET SALES $4,331.3 MILLION VERSUS $3,587.7 MILLION.AGREED, SUBJECT TO APPROVAL BY COURT, TO A $264 MILLION SETTLEMENT TO RESOLVE EPIPEN AUTO-INJECTOR INDIRECT PURCHASER CLASS ACTION CASES.Q4 EARNINGS PER SHARE VIEW $0.83, REVENUE VIEW $4.35 BILLION -- REFINITIV IBES DATA.FY2022 REVENUE VIEW $17.60 BILLION -- REFINITIV IBES DATA.AGREED, SUBJECT TO APPROVAL BY COURT, TO A $264 MILLION EPIPEN SETTLEMENT WHILE DENYING ANY ALLEGATION OF WRONGDOING.",
        "parentTopics": "Corporate Guidance"
    },
    "4543102": {
        "id": 4543102,
        "significance": "1",
        "headline": "Viatris Reports First-Quarter 2022 Results",
        "description": "May 9 (Reuters) - Viatris Inc <VTRS.O>::VIATRIS REPORTS STRONG FIRST-QUARTER 2022 RESULTS.QTRLY TOTAL REVENUES WERE $4.19 BILLION.CONFIRMS BIOCON BIOLOGICS TRANSACTION ON TRACK FOR SECOND HALF 2022 CLOSE.QTRLY EARNINGS PER SHARE $0.33.SEES 2022 TOTAL REVENUE $17.0 BILLION - $17.5 BILLION.Q1 EARNINGS PER SHARE VIEW $0.83, REVENUE VIEW $4.23 BILLION -- REFINITIV IBES DATA.FY2022 REVENUE VIEW $17.24 BILLION -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4619461": {
        "id": 4619461,
        "significance": "1",
        "headline": "Viatris Announces Two Acquisitions",
        "description": "Nov 7 (Reuters) - Viatris Inc <VTRS.O>::VIATRIS ANNOUNCES TWO ACQUISITIONS TO CREATE WHAT IT EXPECTS TO BE A LEADING OPHTHALMOLOGY FRANCHISE; PLANS TO PROVIDE STRATEGIC UPDATE ON ITS FEBRUARY 2022 INVESTOR EVENT.VIATRIS INC - EXPECTS BIOCON BIOLOGICS TRANSACTION TO CLOSE SHORTLY.VIATRIS INC - ENTERS AGREEMENTS TO ACQUIRE OYSTER POINT PHARMA AND FAMY LIFE SCIENCES FOR AGGREGATE OF $700-$750 MILLION IN CASH.VIATRIS INC - EXPECTS COMBINATION OF ACQUISITIONS AND SHARE REPURCHASES TO BE ACCRETIVE TO ADJUSTED EPS IN 2023 ON A STANDALONE BASIS.VIATRIS INC - ANTICIPATES ACQUISITIONS WILL HAVE POTENTIAL TO ADD AT LEAST $1 BILLION IN NET SALES AND AT LEAST $500 MILLION IN ADJUSTED EBITDA BY 2028.VIATRIS INC - REAFFIRMS TOTAL PRE-TAX PROCEEDS EXPECTED FROM BIOCON TRANSACTION & CERTAIN NON-CORE ASSET DIVESTITURES TO BE UP TO APPROXIMATELY $9 BILLION.VIATRIS INC - ALSO EXPECTS TO ACQUIRE FAMY LIFE SCIENCES, WHICH HAS A COMPLEMENTARY OPHTHALMOLOGY PORTFOLIO.",
        "parentTopics": "Corporate Guidance"
    },
    "4667722": {
        "id": 4667722,
        "significance": "1",
        "headline": "Viatris Inc Remains On Track To Execute Planned Divestitures",
        "description": "Feb 27 (Reuters) - Viatris Inc <VTRS.O>::VIATRIS REPORTS STRONG FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES 2023 FINANCIAL GUIDANCE.REMAINS ON TRACK TO EXECUTE PLANNED DIVESTITURES.REAFFIRMS 2024 PHASE 2 OUTLOOK FROM NOVEMBER 7 STRATEGIC UPDATE.QTRLY TOTAL REVENUES $3,876.0 MILLION VERSUS $4,341.6 MILLION.QTRLY EARNINGS PER SHARE $ 0.83.SEES 2023 TOTAL REVENUES $15.5 BILLION - $16.0 BILLION.SEES 2023 ADJUSTED EBITDA $5.0 BILLION- $5.4 BILLION.U.S. GAAP NET CASH PROVIDED BY OPERATING ACTIVITIES FOR 2023 IS ESTIMATED TO BE BETWEEN $2.8 BILLION AND $3.1 BILLION.Q4 EARNINGS PER SHARE VIEW $0.72, REVENUE VIEW $3.97 BILLION -- REFINITIV IBES DATA.FY2023 REVENUE VIEW $15.57 BILLION -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4704986": {
        "id": 4704986,
        "significance": "1",
        "headline": "Viatris sees Outlook FY revenue USD 15,500-16,000 million",
        "description": "May 8 (Reuters) - Viatris Q1 free cash flow USD 923.4 million.:.",
        "parentTopics": "Corporate Guidance"
    },
    "4745839": {
        "id": 4745839,
        "significance": "1",
        "headline": "Viatris Q2 Revenue USD 3,909.5 Million Vs. IBES Estimate USD 3,866 Million",
        "description": "Aug 07 (Reuters) - Viatris Q2 gross margin 41.1%.:.",
        "parentTopics": "Corporate Guidance"
    },
    "4830116": {
        "id": 4830116,
        "significance": "1",
        "headline": "Viatris Q4 Free Cash Flow USD 314 Million",
        "description": "Feb 28 (Reuters) - Viatris Q4 revenue USD 3,830 million vs. IBES estimate USD 3,870 million.:.",
        "parentTopics": "Corporate Guidance"
    }
}